MedTrace Logo

A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking

NCT03958071 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13264

Last updated 2021-11-15

Study results available
· View outcomes & findings →

Summary

To understand differences in characteristics of Idiopathic Pulmonary Fibrosis (IPF) patients who are prescribed nintedanib compared to those who are prescribed pirfenidone.

Conditions

Interventions

DRUG

Nintedanib

Nintedanib initiators

DRUG

Pirfenidone

Pirfenidone initiators

OTHER

Untreated Cohort

Untreated

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-05-31
Completion
2019-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03958071 on ClinicalTrials.gov